To this end, we made five different versions of the CD19 targeting FiCAR and additionally designed CARs where we replaced the CD19 targeting scFv with ones targeting HER-2 (a breast cancer antigen) and GD2 (neuroblastoma antigen). This evidence concerns the gene CD19 and neuroblastoma.